Tag: naltrexone

A detailed clinical guide to Vivitrol (extended-release naltrexone injection) for opioid and alcohol use disorders, covering pharmacology, candidacy criteria, injection protocols, efficacy data, and integration with comprehensive treatment programs in Orange County.

Naltrexone addresses the neurobiological dimension of addiction but cannot on its own resolve the psychological, relational, and social factors that drive substance use disorders. This guide examines the evidence for combining naltrexone with CBT, motivational interviewing, peer support, and other behavioral therapies for superior recovery outcomes.

Naltrexone offers a non-agonist, non-addictive MAT option for opioid use disorder that is free from diversion risk. This guide covers the clinical evidence, detox prerequisites, patient selection, and how naltrexone compares to buprenorphine and methadone for OUD treatment.

Naltrexone is one of only three FDA-approved medications for alcohol use disorder, with robust clinical evidence supporting its ability to reduce heavy drinking days, prevent relapse, and lower overall alcohol consumption. This guide reviews the evidence, dosing strategies, and what patients can realistically expect.

Medication-assisted treatment (MAT) combines FDA-approved medications with behavioral therapy to treat substance use disorders effectively. This guide explains how medication-assisted treatment works, which medications are used for opioid and alcohol addiction, and why MAT is considered the gold standard of care at treatment centers across Southern California.

A clinically grounded comparison of oral naltrexone (ReVia) and extended-release injectable naltrexone (Vivitrol), covering pharmacology, adherence data, cost considerations, and which formulation best supports long-term recovery.